Issuu on Google+

ReportsnReports | Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018 GlobalData, the industry analysis specialist, has released its new report, “Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global endometriosis market. The report identifies the key trends shaping and driving the global endometriosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global bronchitis therapeutics market was valued at $5,984m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.9% to reach $6,931m by 2018. The current market is subdivided into acute bronchitis and chronic bronchitis. The acute bronchitis market is mainly served by generic antibiotics such as azithromycin, clarithromycin, erythromycin, sulfamethoxazole and trimethoprim. The therapies for chronic bronchitis includes drug classes such as bronchodilators, inhaled corticosteroids and other combination therapies. The bronchitis therapeutics market has registered high growth of 13.6% during 2005 to 2010. This is due to the growth in the patient population during 2005–2010 and the increased uptake of novel products such as Advair/Seretide (fluticasone propionate and salmeterol fixed dose combination), Spiriva (tiotropium) and Symbicort (budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg). Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends). Scope The report provides information on the key drivers and challenges of the bronchitis therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) bronchitis market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidate fall under major therapeutic class of LABA, LAMA and combination therapies of LABA/ICS and others. - Analysis of the current and future competition in the global bronchitis therapeutics market. Key market players covered are GlaxoSmithKline, Novartis AG, AstraZeneca PLC, Almirall S.A., Orion Corporation and Merck & Co. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bronchitis therapeutics market. - Analysis of key recent licensing and partnership agreements in bronchitis therapeutics market. Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and


technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global bronchitis market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bronchitis market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global bronchitis market landscape? – Identify, understand and capitalize. Table of Contents 1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 8 2 Bronchitis Therapeutics: Executive Summary 10 2.1 Bronchitis Therapeutics Market is Forecast to Show Slow Growth until 2018 10 2.2 Current Treatment Options are Moderately Successful in Catering to the Current Market Need 11 2.3 Strong Bronchitis Therapeutics Pipeline with Several First-In-Class Molecules 12 2.4 Unmet Needs in the Bronchitis Therapeutics Market 12 3 Bronchitis Therapeutics: Introduction 14 3.1 Disease Overview 14 3.1.1 Forms of Bronchitis: 16 3.2 Epidemiology 19 3.3 Etiology and Pathophysiology 20 3.4 Risk factors for Bronchitis 23 3.5 Signs and Symptoms 23 3.6 Prognosis: 24 3.7 Diagnosis 25 3.8 Referral Pathway 25 3.9 Treatment and Management Pattern 26 3.10 GlobalData Pipeline Report Guidance 30 4 Bronchitis Therapeutics: Market Characterization 31 4.1 Overview 31 4.2 Bronchitis Therapeutics Market Size (2005–2010) – Global 31 4.3 Bronchitis Therapeutics Market Forecast (2010–2018) – Global 33 4.4 Bronchitis Therapeutics Market Size (2005–2010) – The US 35 4.5 Bronchitis Therapeutics Market Forecast (2010–2018) – The US 36 4.6 Bronchitis Therapeutics Market Size (2005–2010) – France 37 4.7 Bronchitis Therapeutics Market Forecast (2010–2018) – France 38


4.8 Bronchitis Therapeutics Market Size (2005–2010) – Germany 39 4.9 Bronchitis Therapeutics Market Forecast (2010-2018) – Germany 40 4.10 Bronchitis Therapeutics Market Size (2005–2010) – Italy 41 4.11 Bronchitis Therapeutics Market Forecast (2010–2018) – Italy 42 4.12 Bronchitis Therapeutics Market Size (2005–2010) – Spain 44 4.13 Bronchitis Therapeutics Market Forecast (2010–2018) – Spain 45 4.14 Bronchitis Therapeutics Market Size (2005–2010) – The UK 46 4.15 Bronchitis Therapeutics Market Forecast (2010–2018) – The UK 47 4.16 Bronchitis Therapeutics Market Size (2005–2010) – Japan 48 4.17 Bronchitis Therapeutics Market Forecast (2010–2018) – Japan 50 4.18 Drivers and Barriers for the Bronchitis Therapeutics Market 51 4.18.1 Drivers for the Bronchitis Therapeutics Market 51 4.18.2 Barriers for the Bronchitis Therapeutics Market 51 4.19 Opportunity and Unmet Need Analysis 52 4.19.1 Opportunity and Unmet Need in the Bronchitis Therapeutics Market 52 4.20 Key Takeaway 54 5 Bronchitis Therapeutics: Competitive Assessment 55 5.1 Overview 55 5.2 Strategic Competitor Assessment 55 5.3 Product Profile for the Major Marketed Products in the Bronchitis Therapeutics Market 56 5.3.1 Spiriva HandiHaler (tiotropium bromide inhalation powder) 56 5.3.2 Foradil Aerolizer (formoterol fumarate inhalation powder) 58 5.3.3 Symbicort (budesonide/formoterol fumarate dihydrate) 160/4.5µg 59 5.3.4 Advair Diskus (fluticasone propionate/salmeterol) 250/50µg 61 5.3.5 Arcapta/Onbrez Breezhaler (indacaterol maleate) 63 5.3.6 Daliresp (roflumilast) Tablet 64 5.3.7 Atrovent HFA (ipratropium bromide) 65 5.3.8 Combivent (ipratropium bromide and albuterol sulfate) 66 5.3.9 Antibiotics 67 5.4 Key Takeaway 69 6 Bronchitis Therapeutics: Pipeline Assessment 70 6.1 Overview 70 6.2 Strategic Pipeline Assessment 70 6.3 Bronchitis Therapeutics Pipeline – Pipeline by Phase of Development 71 6.3.1 Bronchitis Therapeutics – NDA Filed Pipeline 71 6.3.2 Bronchitis Therapeutics – Phase III Clinical Pipeline 71 6.3.3 Bronchitis Therapeutics – Phase II/III Pipeline 72 6.3.4 Bronchitis Therapeutics – Phase II Clinical Pipeline 73 6.3.5 Bronchitis Therapeutics – Phase II/I Clinical Pipeline 75 6.3.6 Bronchitis Therapeutics – Phase I Pipeline 75 6.3.7 Bronchitis Therapeutics – Preclinical Pipeline 76


6.3.8 Bronchitis Therapeutics – Discovery Pipeline 77 6.4 Technology Trends Analytic Framework 78 6.5 Bronchitis Therapeutics Market – Pipeline by Mechanism of Action 80 6.6 Bronchitis Therapeutics – Promising Drugs Under Clinical Development 84 6.7 Molecule Profile for Promising Drugs under Clinical Development 84 6.7.1 Eklira (aclidinium bromide) 84 6.7.2 Andolast (CR 2039) 85 6.7.3 Dulera 86 6.7.4 Erdosteine 87 6.7.5 Fluticasone + Formoterol 87 6.7.6 Glycopyrronium bromide (NVA237) 88 6.7.7 GSK573719 89 6.7.8 Olodaterol (BI 1744 CL) 90 6.7.9 QVA 149 (indacaterol and glycopyrrolate) 91 6.7.10 Relovair 92 6.7.11 Vilanterol (GW642444) 93 6.7.12 Vilanterol + GSK573719 93 6.7.13 Easyhaler Inhalation Corticosteroid/Beta Agonist Fixed Dose Combination 94 6.8 Key Takeaway 95 7 Bronchitis Therapeutics: Clinical Trials Mapping 96 7.1 Clinical Trials by Region/ Country 97 7.2 Clinical Trials by Phase 97 7.3 Clinical Trials by Trial Status 98 7.4 Sponsors 99 7.5 Top Companies Participating in Therapeutics Clinical Trials 100 7.6 Clinical Trials by Region/ Country 101 7.7 Clinical Trials by Phase 102 7.8 Clinical Trials by Trial Status 103 7.9 Sponsors 104 7.10 Top Companies Participating in Therapeutics Clinical Trials 107 7.11 Clinical Trials by Region/ Country 108 7.12 Clinical Trials by Phase 109 7.13 Clinical Trials by Trial Status 110 7.14 Sponsors 111 7.15 Top Companies Participating in Therapeutics Clinical Trials 114 8 Bronchitis Therapeutics: Strategic Assessment 116 8.1 Key Events Impacting the Future Market 116 8.2 Implications for Future Market Competition 117 9 Bronchitis Therapeutics: Future Players 119 9.1 Introduction 119 9.2 Company Profiles 119


9.2.1 GlaxoSmithKline plc 119 9.2.2 Novartis AG 122 9.2.3 AstraZeneca PLC 125 9.2.4 Merck & Co., Inc. 128 9.2.5 Forest Laboratories, Inc. 131 9.2.6 Boehringer Ingelheim GmbH 133 9.2.7 Almirall, S.A. 134 9.2.8 Orion Corporation 136 9.2.9 Rottapharm Madaus 137 9.2.10 Ache Laboratorios Farmaceuticos S/A 139 9.2.11 Other Companies in the Bronchitis therapeutics market 140 10 Bronchitis Therapeutics: Licensing and Partnership Deals 146 11 Bronchitis Therapeutics: Appendix 150 11.1 Market Definitions 150 11.2 Abbreviations 150 11.3 Research Methodology 152 11.4 Bibliography 156 Latest Market Research Reports: Annual Forecasting Food & Grocery 2015 Global Small and Medium Scale LNG Industry Outlook to 2015 Offshore Wind Industry – Growth Potential Hampered by Issues in Supply Chain and Financing Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Drug Eluting Balloons (DEB) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 Austria Power Market Outlook to 2030 - Business Propensity Indicator (BPI), Market Trends, Regulation and Competitive Landscape Angina Pectoris Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018 Chemotherapy-Induced Neutropenia (CIN) Therapeutics –Pipeline Assessment and Market Forecasts to 2018 About Us: ReportsnReports.com is an online market research library of 135,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Visit http://www.reportsnreports.com/ for more details. Contact: Priyank Tiwari 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-391-5441 sales@reportsandreports.com


Visit our Market Research Blog @ http://www.reportsnreportsblog.com/ Connect with us on: Twitter @ http://www.twitter.com/marketsreports Facebook @ http://www.facebook.com/pages/ReportsnReports/191441427571689 LinkedIn @ http://www.linkedin.com/company/reportsnreports


ReportsnReports | Bronchitis Therapeutics- Pipeline Assessment and Market Forecasts to 2018